<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of this study was to evaluate the effects of MRZ 2/579, an uncompetitive <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>, on <z:mpath ids='MPATH_124'>infarct</z:mpath> size, extent of swelling and neurological deficit in a model of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>Physiologically controlled Sprague-Dawley rats received 2 h MCAo by retrograde insertion of an intraluminal suture coated with poly-<z:chebi fb="0" ids="18019,29967">L-lysine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The agent (MRZ 2/579) or vehicle (<z:chebi fb="40" ids="26710">sodium chloride</z:chebi> 0.9%) was administered i.v. immediately after suture removal following a 2-h period of MCAo </plain></SENT>
<SENT sid="3" pm="."><plain>Two experimental groups were studied: group A was treated by vehicle (bolus infusion:1 ml/kg for 10 min followed by infusion of 6 ml/kg/h over 6 h) </plain></SENT>
<SENT sid="4" pm="."><plain>Group B was treated by MRZ 2/579 (bolus infusion:10 mg/kg for 10 min followed by infusion of 6 mg/kg/h over 6 h) </plain></SENT>
<SENT sid="5" pm="."><plain>The neurological status was evaluated during occlusion (at 60 min) and daily for 3 days after MCAo </plain></SENT>
<SENT sid="6" pm="."><plain>Brains were then perfusion-fixed, and <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes and <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e> were determined </plain></SENT>
<SENT sid="7" pm="."><plain>MRZ 2/579 significantly improved the neurological score compared to vehicle-treated rats at 48 h (6.2+/-0.6 and 8.7+/-0.5, respectively; P&lt;0.004) and 72 h after MCAo (5.2+/-0.6 and 8.4+/-0.5, respectively; P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with MRZ 2/579 also significantly reduced total <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (29.3+/-11.1 and 83.2+/-16.5 mm(3), respectively; P&lt;0 </plain></SENT>
<SENT sid="9" pm="."><plain>01), cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (24.8+/-11.2 and 70.0+/-18.0 mm(3), respectively; P&lt;0.04) and <z:e sem="disease" ids="C0751014" disease_type="Disease or Syndrome" abbrv="">subcortical infarction</z:e> (21.2+/-4.1 and 49 </plain></SENT>
<SENT sid="10" pm="."><plain>6+/-4.5 mm(3), respectively; P&lt;0.0002) </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">Brain swelling</z:e> was also markedly reduced compared with vehicle-treated rats (4.7+/-1.3 and 10.8+/-2.1%, respectively; P&lt;0.02) </plain></SENT>
<SENT sid="12" pm="."><plain>These results demonstrate that treatment with MRZ 2/579, when administered promptly after reperfusion, confers neuroprotective effects on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e>, and neurological score compared to the vehicle group </plain></SENT>
</text></document>